Rett Syndrome Drug Receives Positive European Opinion: Rare-Disease Hope and Questions Behind Neuren’s Share Price Surge

For patients with Rett syndrome and their caregivers, any drug advance that can improve daily function and behavioral symptoms is more than a fluctuation in capital markets. Shares of Australia’s Neuren Pharmaceuticals jumped 36% after a positive European regulatory signal. On the surface, this was investors repricing the company; at a deeper level, it reflected expectations that treatment options for a rare neurodevelopmental disease may expand.

The development came from a positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use on Daybu, recommending approval for the treatment of neurobehavioral symptoms in Rett syndrome. Daybu is the brand name used by Acadia Pharmaceuticals in Europe; the same ingredient, trofinetide, is already marketed in the United States as Daybue. Investor’s Business Daily reported that Acadia’s shares also rose 6.8% after the news.

Rett syndrome is seen mostly in females. After a period of early development in infancy and early childhood, patients typically experience regression in purposeful hand movements, language, walking, and coordination, along with breathing, feeding, seizure, or behavioral problems. For diseases of this kind, the treatment goal is often not to “cure” a single cause, but to find measurable improvements, within limited and complex clinical endpoints, that can reduce the burden on patients and families.

This shift in Europe’s position is especially notable because CHMP had previously taken a negative stance on the drug. According to analysts cited by Investor’s Business Daily, the points of controversy included the pivotal trial’s use of the Rett Syndrome Behavioral Questionnaire to assess efficacy, the possibility that more apparent gastrointestinal side effects could affect blinding, and whether the trial results could be extrapolated to real-world use. Acadia subsequently requested a re-examination, leading to this positive opinion.

This is also a reminder that a positive opinion does not mean the drug has formally been launched in the European Union. CHMP recommendations are usually sent to the European Commission for a final decision, so the market adjusted the probability of approval upward; but in clinical use, physicians and families will still have to face known tolerability issues such as diarrhea and vomiting, as well as differences in individual patient responses.

From an industry perspective, Neuren’s sharp share price rise reflects investors seeing the possibility of the European market opening up; Acadia, meanwhile, benefits from an improved sales outlook outside the United States. In the IBD report, RBC analysts estimated that Daybu’s peak sales outside the United States could reach about $240 million, but this remains an analyst model, not a clinical guarantee, and not regulatory approval itself.

The value of rare-disease drugs is often amplified by share prices, and can also easily be obscured by them. If Daybu is ultimately approved in Europe, it will give families affected by Rett syndrome one more treatment option that has undergone regulatory review. At the same time, it will also bring a harder question into clinical practice: in a disease marked by heterogeneous symptoms, heavy caregiving burdens, and limited trial sizes, how should one judge how much a given improvement truly matters to a patient’s life?